Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
-
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
-
Viking's stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
-
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
-
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
-
This weight-loss ETF has performed well in its -2-
Trading Information
- Previous Close Price
- $64.11
- Day Range
- $62.57–65.67
- 52-Week Range
- $8.28–99.41
- Bid/Ask
- $64.51 / $64.96
- Market Cap
- $7.20 Bil
- Volume/Avg
- 2.1 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 30
Comparables
Valuation
|
Metric
|
VKTX
|
RCKT
|
HRTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.71 | 3.80 | — |
Price/Sales | — | — | 2.34 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VKTX
|
RCKT
|
HRTX
|
|---|---|---|---|
Quick Ratio | 37.55 | 7.42 | 1.76 |
Current Ratio | 37.69 | 7.79 | 2.38 |
Interest Coverage | — | −143.43 | — |
Quick Ratio
VKTX
RCKT
HRTX
Profitability
|
Metric
|
VKTX
|
RCKT
|
HRTX
|
|---|---|---|---|
Return on Assets (Normalized) | −11.92% | −41.09% | −11.68% |
Return on Equity (Normalized) | −12.36% | −46.72% | — |
Return on Invested Capital (Normalized) | −17.06% | −47.69% | −18.15% |
Return on Assets
VKTX
RCKT
HRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gcnmdply | Sxm | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fxlcgrrp | Fgxkl | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Whtsczrp | Yrpcq | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hrczcrg | Ddgqvzd | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Hdtkjbxj | Jwznj | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rpgjzfswr | Qkxd | $28.5 Bil | |||
| Moderna Inc
MRNA
| Ljlytzsk | Lpg | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Mxvbwmc | Cjvr | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sydzjgsy | Szcfp | $13.0 Bil | |||
| Incyte Corp
INCY
| Dftkczqg | Tlcwlx | $12.9 Bil |
United States